PHVS Pharvaris N.V. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1830487 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | 124.48M | 98.56M |
| SG&A expense | 45.34M | 47.12M |
| Operating income | -173.71M | -132.40M |
| Pretax income | -173.71M | -132.40M |
| Income tax | 1.99M | 1.83M |
| Net income | -175.70M | -134.22M |
| EPS (basic) | -2.97 | -2.48 |
| EPS (diluted) | -2.97 | -2.48 |
| Weighted avg. shares (diluted) | 59.16M | 54.02M |
| Banking | ||
| Net interest income | 6.54M | 5.47M |
| Balance sheet | ||
| Cash & equivalents | 291.68M | 280.73M |
| Receivables | 4.55M | 2.94M |
| PP&E, netmay include right-of-use assets (IFRS) | 642,470 | 667,000 |
| Total assets | 301.45M | 291.37M |
| Total liabilities | 30.18M | 23.61M |
| Shareholders' equity | 271.27M | 267.76M |
| Cash flow statement | ||
| Operating cash flow | -137.07M | -120.13M |
| Capital expenditure | 164,619 | 538,086 |
| Free cash flow | -137.24M | -120.67M |
| Investing cash flow | -164,619 | -538,086 |
| Financing cash flow | 160.61M | 2.68M |
| Stock-based compensation | 19.05M | 16.21M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.